SD Biosensor Inc

SD Biosensor Inc has a liquidity position that appears to be medium risk, with a current ratio of 2.64 and a cash and equivalents balance of KRW 366.8 billion. However, the company's free cash flow is negative at KRW -461.1 billion, and capital expenditures are also negative at KRW -57.5 billion, indicating ongoing investment or operational cash outflows. The debt-to-equity ratio is 0.29, suggesting a relatively conservative capital structure with limited leverage.

Profitability metrics are sharply negative, with a return on equity of -21.98% and a return on assets of -15.79%. These figures indicate that the company is not generating returns for shareholders or asset holders and is instead experiencing losses. The operating income is negative at KRW -84.7 billion, and the net income is also negative at KRW -51.2 billion, reflecting a challenging financial performance.

The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the healthcare diagnostics sector, which is sensitive to regulatory and demand shifts.

Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a decline in revenue, with no clear indication of a turnaround in the next fiscal year. The negative operating and net income figures suggest that the company is not currently on a path to profitability, and without significant operational or strategic changes, the outlook remains challenging.

Risk factors include the company's negative free cash flow and the potential for dilution, although the risk of dilution is currently assessed as low. The company's liquidity risk is moderate, but the negative net cash position after subtracting total debt raises concerns about its ability to meet short-term obligations without additional financing.

Recent events include the company's continued investment in R&D and capital expenditures, as well as its efforts to expand its product portfolio in the diagnostic market. However, these efforts have not yet translated into improved financial performance, and the company remains unprofitable. No major regulatory or legal events have been reported in the latest filings, but the ESG controversies score of 100.00 suggests that the company has not been involved in any significant controversies.